Jefferies Financial Group upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a hold rating to a buy rating in a report released on Friday morning, Marketbeat reports. They currently have $11.00 price objective on the biotechnology company’s stock. Several other research firms have also issued reports on BCRX. Needham & Company LLC reiterated […]